아발로 테라퓨틱스(AVTX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
| Index | RUT | P/E | - | EPS (ttm) | -5.82 | Insider Own | 8.98% | Shs Outstand | 52.9M | Perf Week | 7.08% |
| Market Cap | 1.03B | Forward P/E | - | EPS next Y | 3.7% | Insider Trans | -6.4% | Shs Float | 48.2M | Perf Month | 8.33% |
| Enterprise Value | 0.95B | PEG | - | EPS next Q | -0.58 | Inst Own | 74.54% | Short Float | 26.32% | Perf Quarter | 40.09% |
| Income | -0.08B | P/S | 17193.45 | EPS this Y | 46.83% | Inst Trans | 21.81% | Short Ratio | 6.34 | Perf Half Y | 23.81% |
| Sales | 0.00B | P/B | 7.03 | EPS next 5Y | 22.98% | ROA | -71.09% | Short Interest | 12.68M | Perf YTD | 7.38% |
| Book/sh | 2.77 | P/C | 12.56 | EPS past 3/5Y | 82.35% 70.2% | ROE | -88.76% | 52W High | -19.65% ($24.27) | Perf Year | 191.48% |
| Cash/sh | 1.55 | P/FCF | - | Sales past 3/5Y | -85.16% -61.19% | ROIC | -120.51% | 52W Low | 214.01% ($6.21) | Perf 3Y | -60.56% |
| Dividend Est. | $0.01 (0.06%) | EV/EBITDA | - | EPS Y/Y TTM | -1121.44% | Gross Margin | -283.05% | Volatility(W/M) | 5.78% 6.87% | Perf 5Y | -99.75% |
| Dividend TTM | - | EV/Sales | 15863.28 | Sales Y/Y TTM | -86.62% | Oper. Margin | -134164.41% | ATR (14) | 1.25 | Perf 10Y | -99.72% |
| Dividend Ex-Date | - | Quick Ratio | 7.66 | EPS Q/Q | 21.93% | Profit Margin | -143627.12% | RSI (14) | 57.57 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.66 | Sales Q/Q | - | SMA20 | 3.86% ($18.78) | Beta | 0.81 | Target Price | $44.69 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/5/13 | SMA50 | 15.6% ($16.87) | Rel Volume | 0.58 | Prev Close | $18.44 |
| Employees | 33 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 4.42% - | SMA200 | 18.72% ($16.43) | Avg Volume(3M) | 2.00M | Price | $19.5 |
| IPO | 2015/11/13 | Option/Short | Yes/Yes | Trades | 11604 | Volume | 1,168,045 | Change | 5.75% |
Avalo Therapeutics Inc (AVTX) Investment Analysis
What kind of company is Avalo Therapeutics Inc?
🧬 Avalo Therapeutics, ticker AVTX, is a clinical-stage biotech company developing novel antibody therapeutics that target immune-mediated inflammatory diseases. Centered on its lead asset abdakibart (development code AVTX-009), a monoclonal antibody targeting interleukin-1 beta, the company is building a pipeline aimed at chronic inflammatory indications such as hidradenitis suppurativa. With no product revenue of its own, it represents a typical clinical-stage biotech structure in which corporate value is driven by clinical progress and capital raises.
Learn more about Avalo Therapeutics Inc →Key Events
Is it profitable?
What's the outlook?
Did earnings meet expectations?
Is it growing?
Has the stock risen over the long term?
Technical Indicators
Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series
Price · Bollinger Bands · Ichimoku Cloud
- close
- BB Upper
- BB Mid
- BB Lower
- Tenkan
- Kijun
- Cloud (SpanA/B)
Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →
Current price $19.50 above the midline ($18.77). Normal upward flow. Above the Ichimoku cloud (bullish).
MACD (12 · 26 · 9) Expand ▼
An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →
MACD 0.476 · Signal 0.592 · Hist -0.117. Weak directional bias.
RSI(14) · Stochastics %K(14) Expand ▼
RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →
RSI 57.6 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 67.4.
※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.
Is it attractive at this price?
Who owns it?
ETFs holding AVTX
How much does it pay in dividends?
Compare Industry Peers
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| AVTX This Stock | $1.0B | - | 7.0 ▼ | -88.76% ▼ | 0.06% ▼ | +5.8% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
FAQ
What kind of company is 아발로 테라퓨틱스(AVTX)?
아발로 테라퓨틱스(AVTX) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AVTX?
The market cap of AVTX is approximately $1.0B, ranking 2,625 within its sector.
Does AVTX pay dividends?
AVTX has a dividend yield of approximately 0.06%, with an annual dividend of $0.01.
What is the 52-week high and low for AVTX?
AVTX has recorded a 52-week high of $24.27 and a low of $6.21.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.